Source: MPX Bioceutical Corporation
TORONTO, Jan. 03, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (the “Company” or “MPX”) (CSE:MPX) (OTC:MPXEF) today announced that Beth Stavola, Chief Operating Officer, and a Director of MPX, has been appointed to the Board of Trustees of the New Jersey Cannabis Industry Association (“NJCIA”).
The New Jersey Cannabis Industry Association is dedicated to advancing the legalization of cannabis in the State of New Jersey, through the development of sensible policies that promote responsible growth. The NJCIA is looking to become an industry leader for all sectors involved in cannabis including industrial hemp, biotechnology, cultivation, manufacturing, finance, security and consulting services. The Association will work to educate New Jersey legislators and decision makers and help them to navigate the changing face of the cannabis debate and to provide advice and guidance for the development of a well-regulated and responsible industry. An advisory board only, the NJCIA does not provide approval for licensing applicants
“Beth’s appointment to the Board of Trustees at the NJCIA is a reflection of her formidable industry expertise,” said Scott Boyes, Chairman, President and CEO of MPX. “Her depth of practical and regulatory knowledge garnered through the development of successful cannabis businesses in several states is sure to prove invaluable to the Board as it looks to facilitate the development of New Jersey’s burgeoning cannabis industry.”
“I look forward to working with the Board of the NJCIA to help bring cannabis best practices to the State of New Jersey,“ said Beth Stavola. “Building a strong framework based on sound policies will help promote responsible development and generate sustainable economic growth.”
About MPX Bioceutical Corporation
MPX, an Ontario corporation, through its wholly owned subsidiaries in the U.S., provides substantial management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannabis enterprises in Arizona operating under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates wholesale) brands. The successful Health for Life brand operates in the rapidly growing Phoenix Metropolitan Statistical Area.
The recently acquired GreenMart of Nevada NLV, LLC (“GreenMart”) is an award winning licensed cultivation, production and wholesale business, licensed for both the medical and “adult use” sectors in Las Vegas, Nevada, and is already selling wholesale into the Nevada medical cannabis market. GreenMart has also optioned suitable locations and intends to enter the higher-margin retail arena by applying for at least two dispensary licenses in the Las Vegas market which will operate under the “Health for Life” brand.
The Company owns assets in Massachusetts supporting cultivation, production and up to three dispensaries there, and with the closing of this most recent transaction, MPX has added the management of a full-service dispensary in Maryland.
MPX continues to expand its U.S. footprint, and is in the process of acquiring management companies that provide operational and other services to two further dispensaries and one production license in Maryland. The Company also leases a property in Owen Sound, Ontario, for which an application to Health Canada has been made for a cannabis production and sales license. In addition, the Company will continue its efforts to develop its legacy nutraceuticals business.
Cautionary Statement Regarding Forward-Looking Information
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
On behalf of the Board of Directors
MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)
W. Scott Boyes, Chairman, President and CEO
For further information, please contact: